American GLP-1 Medication Guides
Evidence-based information. Learn about semaglutide, tirzepatide, and other GLP-1 receptor agonists. We review clinical trial data, dosing protocols, side effect profiles, and real-world effectiveness.
Semaglutide
★★★★Marketed as Ozempic (diabetes) and Wegovy (weight management). STEP trial data shows 14.9% average weight loss at 68 weeks. Weekly subcutaneous injection.
Tirzepatide
★★★★★Marketed as Mounjaro (diabetes) and Zepbound (weight management). SURMOUNT-1 trial showed 20.9% average weight loss. Dual GIP/GLP-1 agonist, weekly injection.
Compare Medications
Side-by-side comparison of efficacy, dosing, costs, and side effects across GLP-1 medications.
Side Effects Guide
Common and serious side effects, frequency data from trials, and management strategies.
Cost Guide
Pricing breakdown, insurance coverage, savings programs, and telehealth alternatives.
Based on Clinical Trial Data
American scientific standards. Our medication guides cite specific trials, regulatory filings, and peer-reviewed research. We report findings as published—no exaggeration, no cherry-picking.
Semaglutide trial program
Tirzepatide trial program
Typical trial duration
Approved medications only
🇺🇸Medical Disclaimer
Your health, your doctor. This information is for educational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and medical supervision. We are not healthcare providers. Talk to your doctor about whether these medications are appropriate for your individual health situation, including potential risks, benefits, and alternatives.